• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Biovica International

0.36 SEK

-1.11 %

Less than 1K followers

BIOVIC B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.11 %
-1.11 %
-1.39 %
-3.78 %
-3.78 %
-53.28 %
-93.96 %
-99.11 %
-96.53 %

Biovica International is a pharmaceutical company that focuses its research on cancer treatment. The company develops blood-based biomarker tests to monitor and evaluate cancer treatments. The tests analyze the risk of developing the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main focus is on the treatment of breast cancer. Biovica International was founded in 2008 and is headquartered in Uppsala.

Read more
Market cap
103.92M SEK
Turnover
229.63K SEK
Revenue
13.38M
EBIT %
-524.06 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Biovica is a Swedish biotechnology company founded in 2009. It was listed on the stock exchange in 2017. Its main product is the DiviTum TKa test: https://divitum.com/, which is a biomarker test that monitors and predicts treatment response in breast cancer. They received FDA approval...
8/31/2025, 1:45 PM
by OSAKEURPO
5
Biovica Q1 Interim report May 2025 – July 2025 - Biovica International AB 11.9 julkaistu osavuosi Tappio pieneni pikkaisen, mutta ei vielä merkittävää parannusta. Lisää myyntiä vaaditaan, että paastään luvattuun 2026 loppuvuoden voitolliseen tulokseen. Mielenkiinnolla seurailen mit...
9/18/2025, 12:09 PM
by Waldeboy
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10/9
2026

Interim report Q1'27

16/9
2026

General meeting '26

17/12
2026

Interim report Q2'27

Regulatory press release2026-07-01 09:15

Biovica beviljas japanskt patent inom immunonkologi

Biovica International
Regulatory press release2026-07-01 09:15

Biovica granted Japanese patent for immuno-oncology

Biovica International
Regulatory press release2026-06-30 13:00

Correction: Biovica refocuses US commercial strategy and terminates agreement with Tempus AI

Biovica International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-06-30 13:00

Rättelse: Biovica fokuserar om sin kommersiella strategi i USA och avslutar avtalet med Tempus AI

Biovica International
Regulatory press release2026-06-30 12:40

Biovica refocuses US commercial strategy and terminates agreement with Tempus AI

Biovica International
Regulatory press release2026-06-30 12:40

Biovica fokuserar om sin kommersiella strategi i USA och avslutar avtalet med Tempus AI

Biovica International
Regulatory press release2026-06-30 08:00

Biovica International AB - Annual Report for the financial year 2025/2026 published

Biovica International
Regulatory press release2026-06-30 08:00

Biovica International AB - Årsredovisning för verksamhetsåret 2025/2026 publicerad

Biovica International
Press release2026-06-23 09:45

Redeye: Biovica (Q4 Review): Near-Term Estimates Pruned, Long-Term Conviction Intact

Biovica International
Press release2026-06-17 10:00

Redeye: Live Q – Biovica

Biovica International
Regulatory press release2026-06-17 08:00

Bokslutskommuniké 2025-2026

Biovica International
Regulatory press release2026-06-17 08:00

Year-End Report 2025-2026

Biovica International
Regulatory press release2026-05-28 08:30

Ny fas III-data visar att DiviTum® TKa detekterar behandlingsspecifik biologisk respons vid spridd bröstcancer

Biovica International
Regulatory press release2026-05-28 08:30

New phase III translational data show DiviTum® TKa captures treatment-specific biological response in metastatic breast cancer

Biovica International
Regulatory press release2026-05-26 08:45

Biovica erhåller utökat arbetsuppdrag från kliniskt onkologibolag för nästa generations CDK-hämmarprogram

Biovica International
Regulatory press release2026-05-26 08:45

Biovica receives expanded work order from clinical-stage oncology company for next-generation CDK inhibitor program

Biovica International
Regulatory press release2026-05-05 21:30

Biovica International AB meddelar förändring i bolagsledningen

Biovica International
Regulatory press release2026-05-05 21:30

Biovica International AB announces change in executive management

Biovica International
Regulatory press release2026-04-30 10:00

Nya ESMO-data belyser TKa i flera behandlingssituationer

Biovica International
Regulatory press release2026-04-30 10:00

New ESMO data highlights TKa across multiple treatment settings

Biovica International